This report is a comprehensive overview of the current state of the 3D in vitro models market and research. The current version reviewed the advantages of 3D models compared to 2D cell cultures, the limitations, and the fields of application of these models and their techniques of production. It delivers advanced market profiling, interactive mindmaps, information about companies and investors, technology application use cases and other actionable information.
Modern Technologies for Preclinical and Clinical Optimisation
Highlights
-- Comprehensive overview of different 3D in vitro models
-- 160 Companies and R&D centres that develop 3D in vitro models and lab automation technologies
-- Database with Key Market players in the development of organoids and organ-on-a-chip models
-- Deep comparison of existing 3D in vitro models, animal models and 2D cultures
-- Overview of chosen companies that develop organoids, organ-on-a-chip and lab automation
Innovative in Vitro Models
Heading 2
To maximise effects and lower costs for both new and existing treatments, Personalised Medicine is receiving a lot of attention in drug development today. So far, drugs have often been approved based on their safety and effectiveness in a variety of patients. The goal of Personalised Medicine is to create patient-tailored treatment plans by accounting for individual variability in medication response. It is the antithesis of the 'one drug fits all' approach. Particularly, with regard to ex vivo treatment response prediction and associated medication dose optimisation, patient- and disease-specific drug testing systems based on current advancements in stem cell, organoid, and organ-on-a-chip technology would deliver great value. In this report, we are focusing on 3D human (multi)cellular assays, including organoids and organ-on-a-chip models, as well as on technologies that can potentially be used for their development, which include microfluidics and lab automation.
Benefits of in Vitro Models: Biological Reason
The immensely complex processes of the human body cannot be accurately modeled by in vivo animal models, and there is growing concern regarding the morality of animal research. A system like an in vitro 2D cell culture model is frequently employed since it is reasonably priced, simple to use, and capable of gathering a lot of reference data. These models, however, are devoid of an actual extracellular physiological context.
Organoids and organ-on-a-chip technologies have enormous advantages compared to 2D cultures and animal models, which make them a practical platform for different experiments, modeling diseases, and high-throughput screening. In a culture dish, patient-derived organoids can serve as models of human disease. The development of numerous organoids and organ-on-a-chip for drug screening and testing has increased international competition for patents.
Organoids: Key Players
Organ-on-a-Chip Diversity
